Kyle Mikson
Stock Analyst at Canaccord Genuity
(0.74)
# 3,677
Out of 4,712 analysts
66
Total ratings
22.81%
Success rate
-22.6%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGEN Repligen | Initiates: Hold | $165 | $145.54 | +13.37% | 1 | Dec 17, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $6 → $3.5 | $2.39 | +46.44% | 3 | Nov 15, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Buy | $3 | $0.79 | +280.71% | 4 | Nov 14, 2024 | |
| QSI Quantum-Si incorporated | Maintains: Hold | $1.5 → $1 | $3.60 | -72.22% | 3 | Nov 13, 2024 | |
| NTRA Natera | Maintains: Buy | $150 → $165 | $160.26 | +2.96% | 5 | Nov 13, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $95 → $75 | $57.55 | +30.32% | 9 | Nov 6, 2024 | |
| ILMN Illumina | Maintains: Hold | $130 → $145 | $135.27 | +7.19% | 6 | Nov 5, 2024 | |
| CSTL Castle Biosciences | Maintains: Buy | $35 → $42 | $26.83 | +56.54% | 3 | Oct 29, 2024 | |
| TXG 10x Genomics | Maintains: Buy | $32 → $20 | $14.59 | +37.08% | 6 | Oct 10, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3.5 → $3 | $1.86 | +61.29% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $5 | $0.43 | +1,076.47% | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $30.44 | +24.84% | 4 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $25 | $11.06 | +126.04% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $3.5 | $1.48 | +136.49% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.62 | +225.20% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $4.71 | +48.62% | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $0.65 | +7,492.59% | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $1.95 | +874.36% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.74 | +20,115.63% | 1 | Jan 29, 2021 |
Repligen
Dec 17, 2024
Initiates: Hold
Price Target: $165
Current: $145.54
Upside: +13.37%
Akoya Biosciences
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $3.5
Current: $2.39
Upside: +46.44%
Lucid Diagnostics
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $0.79
Upside: +280.71%
Quantum-Si incorporated
Nov 13, 2024
Maintains: Hold
Price Target: $1.5 → $1
Current: $3.60
Upside: -72.22%
Natera
Nov 13, 2024
Maintains: Buy
Price Target: $150 → $165
Current: $160.26
Upside: +2.96%
Exact Sciences
Nov 6, 2024
Maintains: Buy
Price Target: $95 → $75
Current: $57.55
Upside: +30.32%
Illumina
Nov 5, 2024
Maintains: Hold
Price Target: $130 → $145
Current: $135.27
Upside: +7.19%
Castle Biosciences
Oct 29, 2024
Maintains: Buy
Price Target: $35 → $42
Current: $26.83
Upside: +56.54%
10x Genomics
Oct 10, 2024
Maintains: Buy
Price Target: $32 → $20
Current: $14.59
Upside: +37.08%
Pacific Biosciences of California
Aug 8, 2024
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.86
Upside: +61.29%
Jul 30, 2024
Maintains: Hold
Price Target: $3 → $5
Current: $0.43
Upside: +1,076.47%
Jun 4, 2024
Maintains: Buy
Price Target: $30 → $38
Current: $30.44
Upside: +24.84%
Apr 29, 2024
Maintains: Buy
Price Target: $32 → $25
Current: $11.06
Upside: +126.04%
Mar 4, 2024
Reiterates: Buy
Price Target: $3.5
Current: $1.48
Upside: +136.49%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.62
Upside: +225.20%
Nov 15, 2022
Maintains: Buy
Price Target: $8 → $7
Current: $4.71
Upside: +48.62%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $0.65
Upside: +7,492.59%
Jan 29, 2021
Initiates: Overweight
Price Target: $19
Current: $1.95
Upside: +874.36%
Jan 29, 2021
Initiates: Overweight
Price Target: $150
Current: $0.74
Upside: +20,115.63%